Introduction
============

Modern healthcare is dependent on effective antibiotics. As the proportion of resistant bacteria increases, achievements in public health may become at stake and health care procedures which today are perceived as routine will become more risky. Even if resistance levels still are low in Sweden in comparison with other countries, resistance to antibacterial drugs is a global problem and its increase is a major challenge for both Sweden and the rest of the world.[@cky209-B1]

In addition to impact on public health, resistance may also have a significant economic impact on society in terms of additional health care consumption and productivity losses. According to the WHO, appropriate studies quantifying the consequences of resistance to antibacterial drugs in terms of health and economic burden are limited.[@cky209-B2] In particular, studies identifying on-top costs, i.e. the additional resource use associated with resistant versus non-resistant bacteria, are scarce.[@cky209-B6] However, the European Centre for Disease Prevention and Control (ECDC) estimated that antibacterial resistance (ABR) in the EU contributes to 25 000 deaths, and an extra EUR 900 million in hospital costs per year.[@cky209-B7] Similarly, the Centre for Disease Prevention and Control (CDC), estimated that antibiotic-resistant bacteria (including fungi) results in 23 000 deaths per year in the USA.[@cky209-B8] In the UK, the O'Neill review estimated that by 2050 antimicrobial resistance (AMR) (resistance in all types of antimicrobial agents) may contribute to about 10 million deaths per year and a significant reduction of the world's Gross Domestic Product (GDP).[@cky209-B9] However, the relevance of some of the estimates used in the ÓNeill report have been questioned.[@cky209-B12] World Economic Forum stated in their risk report 2013 that 'arguably the greatest risk of hubris to human health comes in the form of *antibiotic-resistant bacteria*'.[@cky209-B13] Finally, it was estimated that the OECD countries together may lose about USD 2.9 trillion in cumulative GDP by 2050 due to AMR.[@cky209-B14]

In 2013, when the updated Swedish strategy to combat antibiotic resistance was launched,[@cky209-B15] the Swedish Government commissioned the Public Health Agency to estimate the economic impact of ABR. To estimate the potential costs until 2030 and 2050, we developed, tested and validated a simulation model that projected annual incidence of five types of mandatorily notifiable resistance; methicillin resistant *Staphylococcus aureus* (MRSA), extended-spectrum beta-lactamase (ESBL) in Enterobacteriaceae, carbapenemase-producing Enterobacteriaceae (CPE), penicillin non-susceptible Pneumococci (PNSP) and vancomycin-resistant Enterococci (VRE). The first part of our study showed an significant increase in the additional resource use due to ABR when duration of treatment for infections and carriership caused by resistant bacteria was compared to similar infections caused by susceptible bacteria.[@cky209-B16]

The aim of this study was to project the additional impact of ABR on total health care consumption and associated costs over the period 2018 until 2030 and 2050, respectively, in the Swedish setting, by using a simulation model, as well as the previous calculations of additional resource use.

Method
======

The microsimulation model
-------------------------

To project the development of ABR in Sweden while taking individual risks of infection into account, we chose a micro approach using the SESIM microsimulation model containing a representative sample of 300 000 individuals from the 9 million Swedish population. The SESIM model was developed in 1997 at the Swedish Ministry of Finance as a tool to analyse distributional effects of potential policy changes within the Swedish national system of study allowances. Since then, SESIM has been used for various policy studies and has also been updated with new modules, for instance health.[@cky209-B17] In this study, we have used and further developed the health module to project development of ABR.

In a microsimulation model the individuals are each represented separately. The state of the individuals is updated annually according to rules and statistical models taking individual attributes and history into consideration, thereby creating dynamics. For example, a person's health state is updated annually using a statistical model that includes among other factors age, sex, marital status, last year's health care consumption and last year's health state. A major advantage with applying a micro approach in this case is the implementation of a realistic demographic forecast. The risk of acquiring a resistant infection is higher among the elderly than among younger, this aspect of an ageing population is included in our model. Other, more general, advantages with micro-simulations in the health domain is that the individuals' history matters (diseases, health care consumption, smoking habits etc.), individual behaviour (response to policies) can easily be incorporated and finally, the possibility to target policies to specific individuals based on their characteristics and history.[@cky209-B18]^,^[@cky209-B19]

Initial risks of contracting a specified resistant bacterium that we used in the model were based on notified cases of the included types of resistance. Data were collected from the national register SmiNet, held by the Public Health Agency of Sweden,[@cky209-B20] to which all cases are reported by laboratories and clinicians along with data on patient age, gender and the specimen type. Both infection and carriership of ESBL, CPE, MRSA, PNSP and VRE are mandatory to report according to the Swedish Communicable Disease Act.[@cky209-B21] In 2016 altogether almost 15 500 cases of notifiable resistance were reported to SmiNet. To improve representativeness in scarce data we pooled all cases reported from 2012 to 2016 by gender and age into 5-year groups for all resistance types but MRSA where we used data for 2012--14 because of an increase in screening for MRSA in 2015 and 2016. Despite aggregation, some age and gender cohorts had zero cases and the calculated risk would then be zero. To avoid this, a small but non-zero risk was used in the model instead.

Cases were reported to SmiNet based on findings of resistant bacteria in a wide variety of sample sites and types. To facilitate data presentation we grouped cases into the most common clinical infections and carriership, respectively. Specific assumptions of health care consumption and mortality in relation to each category of infection or carriership and type of resistance are presented in the [Supplementary table S1](#sup1){ref-type="supplementary-material"}. For example, carriership was assumed to be cleared after one year for all but ESBL, and risk for mortality in blood-stream infection was only increased during the first year.

When modelling the development of ABR we used either linear or exponential trends, based on data from 2012 to 2016 (all trends are presented in [Supplementary table S2](#sup1){ref-type="supplementary-material"}). An exception was made for VRE, for which incidence is associated with outbreaks rather than gradual changes. This was modelled as an annual risk of outbreaks. In case of an outbreak of VRE, it was estimated to cease within four years based on previous national experiences. We also assumed that the development of resistance would not increase the total numbers of infections, but rather that a higher proportion of infections was caused by resistant bacteria, since there has not been a significant increase in infections during the last couple of years.

After implementing risks and trends based on reported data, the simulation model output was an annual number of cases of ABR per type of resistance separated between infections and carriership. Since the model has stochastic elements, we ran the model 30 times to ensure stability of the results. The number of cases generated from the micro-simulations was then used in a health economic model to calculate the costs caused by resistance.

The economic model
------------------

In the economic model we used actual data from national registers and information on resource use for patient care and contact tracing, to quantify the on-top consumption of health care and antibiotics due to resistance. Identification of consumption associated with each case of resistance was feasible due to the widespread use of the social security number in Sweden, making it possible to link registers by the individual. Consumption of prescribed antibiotics and health care (days in hospital care, outpatient visits and primary care visits) was identified for reported cases during the 30 days following sampling date. Cost of prescribed antibiotics was collected from the Prescribed Drug Register, and data on health care consumption from the National Patient Register.[@cky209-B22]^,^[@cky209-B23]

To identify the on-top consumption due to resistance we subtracted the health care consumption due to infections caused by susceptible bacteria, which was estimated as average health care consumption for all infections where data were available (blood-stream infections and pneumonia).[@cky209-B24] For diagnoses where this information was unavailable (urinary tract infections and skin and soft tissue infections) clinical experts were consulted to provide a best estimate. For all cases, except ESBL, all family members were assumed to be contact traced, as requested by law. If the case was a child between 1 and 5 years of age an additional 15 individuals representing peers and teachers in a nursery group were contact traced as well. For VRE, which was assumed to only transmit in hospital environment, an additional 10 individuals were contact traced, representing other patients cared for at the same hospital ward.

Costs for primary care visits were collected from a public pricelist from the southern care region.[@cky209-B25] Costs for hospital days and outpatient visits were derived from the Case Costing Database of the Swedish Association of Local Authorities and Regions (SALAR).[@cky209-B24] Data on extra staff hours associated with contact tracing were provided by Värmland and Stockholm counties, and transformed to costs using standardized salary costs for relevant professional groups. Laboratory costs for contact tracing were collected from the Region Skåne clinical microbiology laboratory price list.[@cky209-B26] Identified health care consumption and costs are presented in the [Supplementary tables S3 and S4](#sup1){ref-type="supplementary-material"}. All costs were discounted by 3% to calculate the present value, according to Swedish guidelines.[@cky209-B27]

The economic model combines the output of the microsimulation model (number of ABR cases) with additional resource use and health care costs, depending on resistance type and infection type. This means that we have only calculated the additional cost from resistance and not the total cost of treating infections.

The study was approved by the Ethical Review Board in Stockholm (dnr. 2013/1840-31/2).

Results
=======

Our simulation suggests that there will be about 32 000 and 71 000 annual cases of ABR in Sweden in 2030 and 2050, respectively. Annual cases of ESBL, which is currently the most frequently reported type of resistance in Sweden (about 70% of all notified cases), is expected to almost double (1.97 times) until 2030 and more than 4-fold (4.52 times) until 2050. The resistance with the greatest increase is CPE with a change factor of 3.44 until 2030 and 8.14 until 2050, as shown in [table 1](#cky209-T1){ref-type="table"}. None of the included types of resistance are projected to decrease over the modelled period. Projections of cases are based on historical trends during the years 2012--16 for each type of resistance over the modelled period.

###### 

Projection of number of cases and change factor per resistance type

  Year            ESBL     CPE    MRSA     PNSP   VRE    Total
  --------------- -------- ------ -------- ------ ------ --------
  2018            11 303   140    3281     127    278    15 129
  2019            12 071   174    3765     138    226    16 374
  2020            12 929   197    4112     137    309    17 684
  2021            13 857   248    4493     130    281    19 009
  2022            14 838   231    5043     153    276    20 541
  2023            15 389   286    5561     178    320    21 734
  2024            16 415   325    5770     190    393    23 093
  2025            17 464   324    6294     172    323    24 577
  2026            18 371   330    6685     190    289    25 865
  2027            19 290   382    7072     187    294    27 225
  2028            20 293   435    7616     186    297    28 827
  2029            21 168   435    7809     196    302    29 910
  2030            22 261   481    8584     222    348    31 896
  --              --       --     --       --     --     --
  2050            51 130   1139   17 794   583    308    70 954
  Change factor                                          
  2030            1.97     3.44   2.62     1.75   1.25   2.11
  2050            4.52     8.14   5.42     4.59   1.11   4.69

The microsimulation model generated a total number of cases for each type of resistance, consisting of individuals with either a clinical infection (blood-stream infection, urinary tract infection, skin and soft tissue infection or pneumonia) or a carriership. Accumulated results by 2030 and 2050, respectively, which are shown in [table 2](#cky209-T2){ref-type="table"}, shows that the largest proportions of ABR are detected in carriers and that urinary tract infections are the second most common infection type.

###### 

Number, and percentage, of cases in 2030 and 2050, divided into infection site and resistance type

  2030                                                                                                                                                                                                                                                                    
  ---------------------------------------- ---------------------------------------------------------------- ---------------------------- ------------------------------------ --------------- ----------------- ----------- --------- ------- --------- ------- --------- -------
  ESBL                                     10 978                                                           49                           1769                                 8               535               2                             8979      40      22 261    100
  CPE                                      22                                                               5                            280                                  58              11                2                             168       35      481       100
  MRSA                                                                                                                                   80                                   1               2469              29                            6035      70      8584      100
  PNSP                                                                                                                                   4                                    2                                             12        5       206       93      222       100
  VRE[^a^](#tblfn1){ref-type="table-fn"}   47                                                               14                                                                                                                                301       86      348       100
                                                                                                                                                                                                                                                                          
  **2050**                                                                                                                                                                                                                                                                
                                           **Urinary tract infection[^a^](#tblfn1){ref-type="table-fn"}**   **Blood-stream infection**   **Skin and soft tissue infection**   **Pneumonia**   **Carriership**   **Total**                                                 
                                           **No.**                                                          **%**                        **No.**                              **%**           **No.**           **%**       **No.**   **%**   **No.**   **%**   **No.**   **%**
                                                                                                                                                                                                                                                                          
  ESBL                                     18 401                                                           36                           13 460                               26              1466              3                             17 803    35      51 130    100
  CPE                                      63                                                               6                            665                                  58              29                3                             382       34      1139      100
  MRSA                                                                                                                                   529                                  3               5043              28                            12 222    69      17 794    100
  PNSP                                                                                                                                   1                                    0                                             9         2       573       98      583       100
  VRE[^a^](#tblfn1){ref-type="table-fn"}   46                                                               15                                                                                                                                262       85      308       100

For VRE we only estimated the number of clinical infection, i.e. they are not divided into urinary tract infection, blood-stream infection and so on.

The annual additional health care costs due to notifiable ABR was calculated to almost EUR 40 million by year 2030 and 75 million by year 2050. The accumulated cost between 2018 and 2030 added up to more than EUR 400 million and more than 1500 million until 2050. Until 2030 the largest proportion, more than EUR 247 million (EUR 958 million until 2050), was due to ESBL, followed by MRSA, CPE, VRE and PNSP which incurred costs of EUR 128 million (EUR 453 million, 2050), EUR 15 million (EUR 58 million, 2050), EUR 13 million (EUR 28 million, 2050) and EUR 2 million (EUR 6 million, 2050), respectively, as presented in [table 3](#cky209-T3){ref-type="table"} (exchange rate EUR 1=SEK 9.9448, per 12 February 2018[@cky209-B28]).

###### 

Projected accumulated costs until 2030 and 2050, respectively, million Euros

  2030                                                                                                                                                                          
  ---------- ----------------------------------------------------------------- ---------------------------- ------------------------------------ --------------- -------------- -----------
  ESBL       189                                                               57                           1                                    --              0              247
  CPE        13                                                                2                            0                                    --              1              15
  MRSA       --                                                                7                            50                                   --              71             128
  PNSP       --                                                                0                            --                                   1               1              2
  VRE        8                                                                 --                           --                                   --              6              13
  Total      210                                                               66                           51                                   1               78             406
                                                                                                                                                                                
  **2050**                                                                                                                                                                      
             **Urinary tract infection** [^a^](#tblfn2){ref-type="table-fn"}   **Blood-stream infection**   **Skin and soft tissue infection**   **Pneumonia**   **Carriers**   **Total**
                                                                                                                                                                                
  ESBL       539                                                               417                          3                                    --              0              958
  CPE        49                                                                7                            1                                    --              2              58
  MRSA       --                                                                42                           169                                  --              243            453
  PNSP       --                                                                0                            --                                   2               4              6
  VRE        16                                                                --                           --                                   --              12             28
  Total      603                                                               466                          172                                  2               261            1 503

For VRE we only estimated the number of clinical infection, i.e. they are not divided into urinary tract infection, blood-stream infection and so on.

As shown in [table 3](#cky209-T3){ref-type="table"}, the total costs in 2030 were dominated by the cost associated with blood-stream and urinary tract infections caused by ESBL and carriership and skin and soft tissue infection caused by MRSA. Blood-stream infections were in general the most expensive per case, but since urinary tract infections are more frequent, the accumulated costs for them were much higher. The high costs of MRSA carriers were mainly due to mandatory contact tracing.

Discussion
==========

In our simulation of a future scenario for the development of notifiable ABR in Sweden we found that the accumulated additional health care costs from 2018 until 2030 and 2050, respectively, would reach more than EUR 400 million and EUR 1500 million, even if we manage to maintain the presently low level of resistance and slow pace of its' increase.

To project the future costs we used a microsimulation model, as widely as possible based on actual data. Inputs and variables were based on reported Swedish surveillance data combined with costs derived from healthcare sources. We used the recent years' trend of ABR as a projection of the future development, instead of assuming hypothetical levels. This, in combination with using actual health care costs, adds realism to our results. In contrast, recently published studies have used hypothetical cases based on assumed potential levels of resistance and made calculations of the economic impact from these assumptions.[@cky209-B8] We therefore believe our results will better guide decisions regarding interventions to keep ABR at the same levels as today.

However, the model still has some limitations. The scenarios in the model are based on today\'s health care structures. The assumption is therefore that patients with resistant bacteria in the future will be treated the same way as today, which would probably not be the case if resistance levels increase significantly. Higher levels of resistance could bring about changes in treatment strategies and infection control strategies, which might affect health care costs due to resistance in the future. In addition, we have not taken the risk of not having last resort antibiotics available as a consequence of changed resistance patterns in the projected period, since development of such resistance (e.g. carbapenemresistant Enterobactriaceae), has been comparatively slow thus far. As this may change, it further contributes to our estimate being conservative. Specific conditions, such as environmental factors, medication routines, ongoing outbreaks and endemic situation, affect both the risk of ABR and impact of various interventions, which are not represented in the model.

In addition to increased consumption of health care, infections with antibiotic-resistant bacteria generate indirect costs, such as production loss from sick leave and disability pension as well as changed routines in the health care sector. In other studies these costs have been assigned a substantial impact from a societal perspective.[@cky209-B7]^,^[@cky209-B9]^,^[@cky209-B29] In this study, however, we only include direct health care costs since we lack reliable data for other costs.

There are many other types of ABR than those notifiable under the Communicable Diseases Act. Since we only included notifiable ABR, and only the health care related costs, it is reasonable to assume that cost estimations are quite conservative. However, the model is prepared to include indirect costs and other types of resistance as a next step when data is available.

According to our projections, the total costs of ABR in 1 year, in 2030 and 2050, respectively, will be almost EUR 40 and 75 million. Other studies have estimated that development of ABR will have a large impact on national and global economies.[@cky209-B7]^,^[@cky209-B14] The difference between our results and other studies can at least partly be explained by the rather low levels and comparatively slower pace of development of ABR in Sweden today, that our study was limited to notifiable resistance, and also that our study to a greater extent was based on actual data rather than assumptions.

In conclusion, by applying a microsimulation model based on actual data of notified ABR, we found that even in Sweden, which still has comparatively limited resistance levels, the additional health care costs due to ABR may increase 4-fold to a yearly cost of EUR 75 million by 2050 and that the accumulated costs 2018--50 would reach more than EUR 1500 million. To improve forecasts and form a better basis for interventions to tackle ABR at national and global level, more valid data on human and economic consequences of ABR in different settings need to be collected.

*Conflicts of interests*: None declared.

Key pointsWe found that the annual additional health care costs due to ABR may increase 4-fold by 2050 and that the additional accumulated health care costs 2018--50 would reach more than EUR 1500 million, even in Sweden, which still has comparatively low resistance levels.Economic analysis of the development of ABR provides important knowledge for informing interventions and strategies to tackle ABR at national and global level.Indirect costs and costs for non-notifiable resistance still remain to be studied.
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###### 

Click here for additional data file.
